Sofosbuvir INN mg and Velpatasvir INN mg tablets \n \nSofosbuvir INN 400?mg and?Velpatasvir INN 100?mg tablets \n \nIngredients?:?Each tablet film-coated tablet containing?400?mg of Suofeibuwei and?100?mg of Zapata Vale Maxwell. \n \nIndications?:?applicable to the treatment?1?,?2?,?3?,?4?,?5?or?6?adult patients with chronic hepatitis C virus infection without cirrhosis or decompensated cirrhosis, decompensated cirrhosis with ribavirin combination. \n \nDosage and Administration?:?Suofobuwei and verapamil The recommended dose is an oral tablet once a day, before and after meals can be.?The recommended duration of treatment options and patient populations based on the following?: \n
\n \n \nPatients standard | \nAnd duration of treatment options | \n
\n \nAnd patients with decompensated cirrhosis patients without cirrhosis | \nSofosbuvir INN 400mg & Velpatasvir 100mg 12?? | \n
\n \nDecompensated cirrhosis (hepatitis B or C) | \nSofosbuvir INN 400mg & Velpatasvir 100mg + ribavarin 12?? | \n
\n \n
\nOr registered in accordance with the doctor's instructions. \n \n
Side effects?:?The most common side effects are fatigue, anemia, nausea, headache, insomnia and diarrhea.?HBV?virus and hepatitis C virus co-infected patients?HVB?potential risk of viral reactivation, and vitamin?K?antagonist interactions and?INR?value changes. \n \nContraindications?:?In patients with disabling ribavirin, disable Suofeibuwei andVelpastavir?ribavirin program?Note?:?when Suofeibuwei with amiodarone and other direct antiviral hepatitis C virus when combined, severe symptomatic bradycardia occurs.?Amiodarone is not recommended with?sofosbuvir / velpatasvir?combination.?Drug interactions?: Sofosbuvir & Velpatasvir?may interact with the following drugs?:?omeprazole, topotecan, carbamazepine, phenytoin, phenobarbital, rifapentine, St. John's Wort. \n \n
Overdose?:?no specific antidote for an overdose of Suofeibuwei?/?verapamil.?If overdose occurs, the patient must be monitored for toxicity.?For pregnant and breast-feeding?:?no studies on pregnant women adequate and well-controlled.?Only when the potential benefits outweigh the potential risk to the fetus, you should use this medication.?It is not known?sofosbuvir & velpatasvir?whether or metabolites excreted in breast milk.?Recommends acceptance?sofosbuvir & velpatasvir?women do not breastfeed. \n \n
Storage?:?stored at?30?deg.] C?or less in a cool dry place.?Dark moisture.?Put the medicine where children are out of reach. \n \n
Packing?:?Each box?28?sheet blister pack.